Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.35 |
| ▸ | SCN4A | P35499 | 3/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.32 |
| ▸ | AKT1 | P31749 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4307454 | 1.00 | TACR1 (0.35) | TACR1SCN4ALTA4HCYP19A1CYP11B1 | |
| SCHEMBL4307461 | 1.00 | TACR1 (0.35) | TACR1SCN4ALTA4HCYP19A1CYP11B1 | |
| SCHEMBL647136 | 0.88 | CHRNA7 (0.34) | LTA4HCYP19A1CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL649516 | 0.88 | MTNR1A (0.35) | CYP19A1CYP11B1CYP11B2ALDH1A1MAPT | |
| SCHEMBL647168 | 0.87 | CHRNA7 (0.34) | CYP19A1CYP11B1CYP11B2ALDH1A1MAPT | |
| SCHEMBL646575 | 0.87 | CYP19A1 (0.35) | CYP19A1CYP11B1CYP11B2ALDH1A1MAPT | |
| SCHEMBL4315071 | 0.86 | LTA4H (0.36) | LTA4HCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL3920744 | 0.86 | LTA4H (0.36) | LTA4HCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL3920272 | 0.86 | FFAR4 (0.46) | — | |
| SCHEMBL3919076 | 0.86 | MTNR1A (0.38) | CYP19A1CYP11B1CYP11B2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | TACR1 1412/4885SCN4A 4741/4885LTA4H 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.